Synopsis
Select, start and monitor biologic DMARDs through the relevant disease and NICE pathway, matching molecular target to phenotype while preventing serious infection, reactivation, organ-specific toxicity and reproductive harm.
- A biologic DMARD is a protein therapeutic targeting a cytokine, receptor or immune cell; choice follows diagnosis, prior DMARD response, NICE eligibility, dominant disease domain, comorbidity and patient preference.
- Do not start during active serious infection. Before treatment, screen for tuberculosis, hepatitis B with HBsAg, anti-HBc and anti-HBs, hepatitis C and HIV, and update vaccination.
- TNF inhibitors treat rheumatoid, psoriatic and axial spondyloarthritis but need special caution with latent TB, demyelination and heart failure; adalimumab is contraindicated in NYHA class III or IV heart failure.
- IL-6 inhibitors can normalise CRP and suppress fever while infection or bowel perforation evolves; monitor neutrophils, platelets, transaminases and lipids as well as symptoms.
- Rituximab depletes CD20-positive B cells. Screen every patient for hepatitis B core antibody as well as surface antigen, measure immunoglobulins and plan vaccines before infusion.
- IL-17 inhibition is effective for axial and psoriatic disease but can increase mucocutaneous candidiasis and may worsen or unmask inflammatory bowel disease; the bowel phenotype influences selection.
- Never combine two biologic DMARDs or a biologic with a JAK inhibitor routinely because serious infection rises without an established benefit.
- Inactivated vaccines are safe but response may be weaker; avoid live vaccines during biologic immunosuppression and time them before treatment when possible.
- Hold treatment through a serious infection or major surgery according to the drug-specific plan; restart only when recovery and wound status are satisfactory.
- Pregnancy and infant-vaccine planning is molecule- and trimester-specific. Some TNF inhibitors are compatible, but placental transfer late in pregnancy can require deferral of infant live vaccines.
Key red flags
Fever, rigors, hypotension, confusion, hypoxaemia, focal neurological change or rapidly progressive infection requires immediate biologic interruption and emergency sepsis assessment.
Persistent cough, weight loss, night sweats, lymphadenopathy or unexplained systemic illness can represent tuberculosis or another opportunistic infection despite a negative pre-treatment screen.
Jaundice or transaminase rise in an HBsAg-positive or anti-HBc-positive patient may represent hepatitis B reactivation, especially after rituximab.
New or worsening dyspnoea, oedema or reduced ejection fraction during TNF inhibition requires heart-failure assessment and specialist withdrawal review.
New optic neuritis, sensory level, focal neurological deficit or demyelinating syndrome during a TNF inhibitor requires urgent neurology and rheumatology review.
Severe abdominal pain, fever or peritonism on an IL-6 inhibitor may indicate gastrointestinal perforation even when CRP is low.
Painful red photophobic eye, active inflammatory bowel disease or recurrent candidiasis during an IL-17 inhibitor can change class suitability and needs coordinated specialty review.
Focal symptoms, weight loss, zoster, dyspnoea, confusion or functional decline may be more informative than fever or CRP during biologic immunosuppression.
Investigation priorities
Exclude active infection and identify reactivation risks before the first biologic dose.
Management branches
Active rheumatic disease remains above target after the required conventional therapy or has a pathway-specific indication.
- Verify diagnosis, inflammatory activity, adherence and NICE criteria and document peripheral, axial, skin, eye and bowel domains plus the patient's priority.
- Compare classes against TB and hepatitis risk, recurrent infection, heart failure, demyelination, IBD, uveitis, malignancy, pregnancy, route and monitoring burden.
- Choose one biologic with an objective response window and a predefined plan for non-response, secondary failure and adverse effects.